bluuebunny/crossref_metadata_2025 huggingface dataset:
Neurological Sweet’s syndrome: a rare but treatable manifestation of an autoinflammatory disease
Authors: Lim Gareth Zigui , Tan Jiekai , Lee Joyce Siong-See , Lim Xin Rong , Yeo Tianrong
Published: December 2024

Sweet's syndrome is an autoinflammatory disease characterised by systemic symptoms and a cutaneous neutrophilic dermatosis. Neurological involvement is rare but important to recognise. Patients may have headache, confusion, seizures, and focal neurological deficits; MR brain scanning may show widespread T2-hyperintense lesions, with a CSF pleocytosis. Clinicians should suspect neurological Sweet’s syndrome in patients with central nervous system dysfunction, who have unexplained fever or systemic inflammation, and a pustular neutrophilic dermatosis. The condition responds well to corticosteroids, which can prevent long-term neurological sequalae.
Potential impacts and priority areas of research of the on-going invasion of green crabs along the SW Atlantic
Authors: Malvé Mariano E. , Battini Nicolás , Cordone Georgina , Cortés Juan I. , Galván David E. , Livore Juan P. , Suárez Nicolás , Yorio Pablo , Schwindt Evangelina , Mendez María M.
Published: December 2024

The European green crab ( Carcinus maenas) is one of the most extensively studied decapod species worldwide, and it currently inhabits every continent except Antarctica. Its effects are observed across various spatio-temporal scales, impacting a wide range of taxa and environments. While extensive research has been conducted in the Northern Hemisphere, populations in the Southern Hemisphere (e.g., Argentina, Australia, and South Africa) have not been thoroughly investigated. This study has three main goals: (1) summarise and contextualise the invasion history of green crabs in the Southwest Atlantic since their initial detection in 2000, (2) present nine case studies identifying the potential ecological and economic impacts of green crabs on coastal ecosystems, and to highlight priority research areas, and (3) discuss appropriate management actions in response to the species' rapid spread in the region. Our findings suggest that green crabs are likely to impact foundation species along rocky shores, alter the physical characteristics of soft-bottom environments, and affect infaunal organisms in sandy shores. Most of these impacts are either occurring or expected to occur in numerous marine protected areas. We also examine green crab interactions with other key species, highlighting its dual role as both an invasive predator and prey for native species, thus serving as a novel food resource. Furthermore, we consider their effects on commercially important species, tourism, and implications for threatened native species. Finally, we recommend prioritising prevention and rapid response strategies for managing green crab invasions, emphasising the importance of early detection and prompt action to address new incursions.
Unraveling the Impact of ChatGPT as a Knowledge Anchor in Business Education
Authors: George Amrita , Storey Veda Catherine , Hong Shuguang
Published: December 2024

The emergence of Large Language Models (LLM), such as ChatGPT, is considered a productivity revolution in many areas of business and society. For a classroom setting, especially, it would be useful to understand whether, and how, to incorporate ChatGPT, similar to any other productivity revolution technology, such as calculators or a Google search engine. Although there are concerns regarding the use of LLMs in business education, the positive or negative impact of LLM use is not well-understood. In this research, we examine the substitution and complementarity effects of using ChatGPT in business curricula on learning outcomes and well-being in a socially supportive learning environment. Specifically, we examine whether technology anchors impact students’ goal orientation, learning outcomes, and well-being by conducting an empirical study with students majoring in Information Systems. Our analysis reveals that a technology anchor (computer playfulness) can complement the effects of social support on learning outcomes, while enhancing well-being for simple tasks. Students’ well-being and learning outcomes are hindered by LLM use (specifically, the computer anxiety anchor), substituting social support for simple and difficult tasks. These findings have implications for educational institutions that are assessing how to incorporate LLMs into business curricula.
Experimental Insights into Quantum Spin Ice Physics in Dipole–Octupole Pyrochlore Magnets
Authors: Smith Evan M. , Lhotel Elsa , Petit Sylvain , Gaulin Bruce D.
Published: December 2024

We review a key subset of the experimental studies that have recently focused on cubic pyrochlore magnets whose pseudospin-1
$/$
2 degrees of freedom have mixed dipolar and octupolar character. We discuss how this comes about and how the character of the pseudospin-1
$/$
2 can be experimentally determined. The minimal spin Hamiltonian for such magnetic insulators is known to give rise to a rich phase diagram with both disordered U(1) quantum spin ice (QSI) states and all-in–all-out (AIAO) noncollinear ordered states, each with dipolar and octupolar character. We focus primarily on experimental studies on two such single crystal systems, the
$\TimesFont{J}$
= 5
$/$
2 Ce2Zr2O7 and the
$\TimesFont{J}$
= 9
$/$
2 Nd2Zr2O7. We make the case that Ce2Zr2O7 is an excellent QSI ground-state candidate material, close to the border between QSIs with dipolar and octupolar symmetry. Nd2Zr2O7 exhibits an AIAO ordered phase, featuring an order parameter consisting of dipolar and octupolar magnetic moments. It is found to reside close to a QSI phase boundary and features dynamic fragmentation in its excitation spectrum.
Multidimensional assessment of exertional dyspnea in young healthy males and females who select unsatisfied inspiration at peak exercise
Authors: Mitchell Reid A. , Hind Alanna S. , Ferguson Olivia N. , Flynn Morgan , Arnold Jem I. , Dhillon Satvir S. , Eves Neil D. , Sheel A. William , Guenette Jordan A.
Published: December 2024

The mechanisms of sex-based differences in the sensation of unsatisfied inspiration (UI) in healthy humans during exercise are poorly understood. We found that females who selected UI at peak exercise had worse dyspnea intensity ratings throughout exercise. Both sexes who selected UI at peak exercise also reported more distressing dyspnea qualities post exercise. Psychosocial factors appeared to influence male dyspnea perception, whereas smaller absolute lung volumes correlated with worse UI ratings in females.
Supplementary Data File from Discovery of RGT-018: A Potent, Selective, and Orally Bioavailable SOS1 Inhibitor for KRAS-Driven Cancers
Authors: Xiao Fei , Wang Kailiang , Wang Xinjuan , Li Huijuan , Hu Zhilong , Ren Xiaoming , Huang Wei , Feng Teng , Yao Lili , Lin Jing , Li Chunlai , Zhang Zhuanzhuan , Mei Liufeng , Zhu Xiaotian , Zhong Wenge , Xie Zhi
Published: December 2024

For cocrystal structure
Supplementary Table S2 from TR-107, an Agonist of Caseinolytic Peptidase Proteolytic Subunit, Disrupts Mitochondrial Metabolism and Inhibits the Growth of Human Colorectal Cancer Cells
Authors: Giarrizzo Michael , LaComb Joseph F. , Patel Hetvi R. , Reddy Rohan G. , Haley John D. , Graves Lee M. , Iwanowicz Edwin J. , Bialkowska Agnieszka B.
Published: December 2024

Supplementary Table S2. Analysis of downregulated proteins upon TR-107 treatment.
Supplementary Figure S9 from TR-107, an Agonist of Caseinolytic Peptidase Proteolytic Subunit, Disrupts Mitochondrial Metabolism and Inhibits the Growth of Human Colorectal Cancer Cells
Authors: Giarrizzo Michael , LaComb Joseph F. , Patel Hetvi R. , Reddy Rohan G. , Haley John D. , Graves Lee M. , Iwanowicz Edwin J. , Bialkowska Agnieszka B.
Published: December 2024

Supplementary Figure S9. TR-107 reduces total ATP production confirming an inactivation of OXPHOS and suppressed glycolytic compensatory response. Colorectal cancer cells (A) LoVo, (B) NCI-H508, (C) LS 174T, and (D) RKO were treated with vehicle control (0.1% DMSO) or indicated concentrations of TR-107 for 12 hours. Quantification of OCR and PER was measured with the Seahorse XF Real-Time ATP Rate Assay. Mitochondrial, glycolytic, and total ATP production rates were calculated using OCR and PER values as described in Materials and Methods. Data are presented as mean ± SD values (N=6). *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
Table S11 from Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2–p53 Antagonist Suitable for Intermittent Dose Schedules
Authors: Gollner Andreas , Rudolph Dorothea , Weyer-Czernilofsky Ulrike , Baumgartinger Rosa , Jung Peter , Weinstabl Harald , Ramharter Jürgen , Grempler Rolf , Quant Jens , Rinnenthal Jörg , Pérez Pitarch Alejandro , Golubovic Bojana , Gerlach Daniel , Bader Gerd , Wetzel Kristiane , Otto Sebastian , Mandl Christian , Boehmelt Guido , McConnell Darryl B. , Kraut Norbert , Sini Patrizia
Published: December 2024

Brigimadlin PK parameters in SJSA-1 osteosarcoma MDM2-amplified xenograft model.
Supplementary Figure S4 from TR-107, an Agonist of Caseinolytic Peptidase Proteolytic Subunit, Disrupts Mitochondrial Metabolism and Inhibits the Growth of Human Colorectal Cancer Cells
Authors: Giarrizzo Michael , LaComb Joseph F. , Patel Hetvi R. , Reddy Rohan G. , Haley John D. , Graves Lee M. , Iwanowicz Edwin J. , Bialkowska Agnieszka B.
Published: December 2024

Supplementary Figure S4. TR-107 treatment dysregulates the cell cycle and leads to cytostatic arrest of CRC cells. Colorectal cancer cells (A) DLD-1, (B) LS1034, (C) HT29, and (D) HCT116 were treated with vehicle control (0.1% DMSO) or indicated concentrations of TR-107 for 24, 48, and 72 hours. Cells were collected at each time point and cell cycle analysis was measured using fluorescence-activated cell sorting (FACS) as described in Materials and Methods. Data are presented as mean ± SD values (N=3). *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
Supplementary Figure S2 from TR-107, an Agonist of Caseinolytic Peptidase Proteolytic Subunit, Disrupts Mitochondrial Metabolism and Inhibits the Growth of Human Colorectal Cancer Cells
Authors: Giarrizzo Michael , LaComb Joseph F. , Patel Hetvi R. , Reddy Rohan G. , Haley John D. , Graves Lee M. , Iwanowicz Edwin J. , Bialkowska Agnieszka B.
Published: December 2024

Supplementary Figure S2. Cell confluence images confirm a dose- and time-dependent inhibition of CRC cell proliferation. Colorectal cancer cells (A) DLD-1, (B) LS1034, (C) HT29, and (D) HCT116 were treated in a 6-well plate format with vehicle control (0.1% DMSO) or indicated concentrations of TR-107 for 24, 48, and 72 hours. Phase-contrast live images (10× zoom) of cell confluence were captured at each time point. Images were processed with ImageJ and cell confluence was measured with PHANTAST 2.0 software as described in Materials and Methods. Data are presented as mean ± SD values (N=9). *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
Supplementary Figure S16 from TR-107, an Agonist of Caseinolytic Peptidase Proteolytic Subunit, Disrupts Mitochondrial Metabolism and Inhibits the Growth of Human Colorectal Cancer Cells
Authors: Giarrizzo Michael , LaComb Joseph F. , Patel Hetvi R. , Reddy Rohan G. , Haley John D. , Graves Lee M. , Iwanowicz Edwin J. , Bialkowska Agnieszka B.
Published: December 2024

Supplementary Figure S16. Co-treatment with TR-107 and Erastin leads to the synergistic inhibition of CRC cell viability. (A-D) Dose response matrices were generated for the CRC cell lines LoVo, NCI-H508, LS 174T, and RKO from each CMS classification. Cells were treated with independent TR-107 (10 nmol/L, 50 nmol/L), Erastin (1 μmol/L, 10 μmol/L), or combinations of the two drugs as described in Materials and Methods. Cell viability was measured with the CellTiter-Glo assay and values were converted to % inhibition for analysis. Analysis was conducted on RStudio using the synergyfinder package. (E-H) Drug synergy scores for Erastin and TR-107 co-treatment were calculated using the Highest Single Agent (HSA) score model. HSA scores less than -10 = antagonistic interaction, between -10 to 0 = additive interaction, and greater than 10 = synergistic interaction. Dose response data are presented as mean ± SD values (N=6). (I-J) Immunoblotting and densitometry analysis of GPX4 expression after 24 hours in HCT116 cells treated with independent TR-107, Erastin, or co-treatment. Western blot data are presented as N=1.
Figure S4 from Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2–p53 Antagonist Suitable for Intermittent Dose Schedules
Authors: Gollner Andreas , Rudolph Dorothea , Weyer-Czernilofsky Ulrike , Baumgartinger Rosa , Jung Peter , Weinstabl Harald , Ramharter Jürgen , Grempler Rolf , Quant Jens , Rinnenthal Jörg , Pérez Pitarch Alejandro , Golubovic Bojana , Gerlach Daniel , Bader Gerd , Wetzel Kristiane , Otto Sebastian , Mandl Christian , Boehmelt Guido , McConnell Darryl B. , Kraut Norbert , Sini Patrizia
Published: December 2024

In vitro activity of brigimadlin in normal cells.
Supplementary Figure S12 from TR-107, an Agonist of Caseinolytic Peptidase Proteolytic Subunit, Disrupts Mitochondrial Metabolism and Inhibits the Growth of Human Colorectal Cancer Cells
Authors: Giarrizzo Michael , LaComb Joseph F. , Patel Hetvi R. , Reddy Rohan G. , Haley John D. , Graves Lee M. , Iwanowicz Edwin J. , Bialkowska Agnieszka B.
Published: December 2024

Supplementary Figure S12. TR-107 treatment reduces integrated stress response and antioxidant protein expression in CRC cells. Immunoblotting of ATF3 and ATF4 and densitometry analysis of colorectal cancer cells (A) LoVo, (B) NCI-H508, (C) LS 174T, and (D) RKO cells treated with TR-107 (50 nmol/L) for 24 and 72 hours indicate a reduction in stress response. Data are presented as mean ± SD values (N=3). *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
Supplementary Figure S10 from TR-107, an Agonist of Caseinolytic Peptidase Proteolytic Subunit, Disrupts Mitochondrial Metabolism and Inhibits the Growth of Human Colorectal Cancer Cells
Authors: Giarrizzo Michael , LaComb Joseph F. , Patel Hetvi R. , Reddy Rohan G. , Haley John D. , Graves Lee M. , Iwanowicz Edwin J. , Bialkowska Agnieszka B.
Published: December 2024

Supplementary Figure S10. TR-107 downregulates the expression of essential mitochondrial proteins. Colorectal cancer cells (A) LoVo, (B) NCI-H508, (C) LS 174T, and (D) RKO were treated with vehicle control (0.1% DMSO) or TR-107 (50 nmol/L) for 24 hours. Immunoblot (N=3) was performed for various mitochondrial regulatory and metabolic proteins. (E-H) Band densitometry analysis was conducted to quantify relative protein expression and normalized to β-actin control. Densitometry was measured with ImageJ and analyzed with GraphPad Prism as described in Materials and Methods. Data are presented as mean ± SD values (N=3). *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
Supplementary Table 2 from Immunoproteasome Activation Expands the MHC Class I Immunopeptidome, Unmasks Neoantigens, and Enhances T-cell Anti-Myeloma Activity
Authors: Rana Priyanka S. , Ignatz-Hoover James J. , Guo Chunna , Mosley Amber L. , Malek Ehsan , Federov Yuriy , Adams Drew J. , Driscoll James J.
Published: December 2024

Supplementary Table 2
Figure S9 from Immunoproteasome Activation Expands the MHC Class I Immunopeptidome, Unmasks Neoantigens, and Enhances T-cell Anti-Myeloma Activity
Authors: Rana Priyanka S. , Ignatz-Hoover James J. , Guo Chunna , Mosley Amber L. , Malek Ehsan , Federov Yuriy , Adams Drew J. , Driscoll James J.
Published: December 2024

Figure S9. Effect of Btz and Compound A alone and combined in a. RPMI-8226, b. ARH77, c. U266 and d. E.G7-Ova cells. Cell viability was determined using the XTT assay. Assays were performed in triplicate. Staurosporine (ST, 2 uM) represents a positive control for cell death.
Figure S2 from Immunoproteasome Activation Expands the MHC Class I Immunopeptidome, Unmasks Neoantigens, and Enhances T-cell Anti-Myeloma Activity
Authors: Rana Priyanka S. , Ignatz-Hoover James J. , Guo Chunna , Mosley Amber L. , Malek Ehsan , Federov Yuriy , Adams Drew J. , Driscoll James J.
Published: December 2024

Figure S2. Methods of synthesis for Compounds A-H and tubastatin-A, ACY-738, ACY-1215 and nexturastat. Compounds A through H were synthesized by ChemDiv as indicated. The step-by-step details for the synthesis of Compounds A through H are shown. ChemDiv custom synthesis products were then subjected to quality control by NMR and LC-MS and purity was guaranteed to be >90%.
Supplementary Figure S3 from Separable Cell Cycle Arrest and Immune Response Elicited through Pharmacological CDK4/6 and MEK Inhibition in RASmut Disease Models
Authors: Wu Jin , Wang Jianxin , O’Connor Thomas N. , Tzetzo Stephanie L. , Gurova Katerina V. , Knudsen Erik S. , Witkiewicz Agnieszka K.
Published: December 2024

Supplementary Figure S3. Volcano plots displaying differentially expressed genes in CDK4/6i (palbociclib, 2 μmol/L) (A) and MEKi (pimasertib, 0.5 μmol/L) (B)-treated HT1080 cells. The RNAseq data was downloaded from the GEO database (GSE180265). C. Heatmap displaying log2 fold change of select cell cycle regulatory genes from HT1080 cells treated with CDK4/6i (palbociclib, 2 μmol/L) or MEKi (pimasertib, 0.5 μmol/L). D. Heatmap displaying log2 fold change of select immune-related genes from HT1080 cells treated with CDK4/6i (palbociclib, 2 μmol/L) or MEKi (pimasertib, 0.5 μmol/L).
Supplemental Table S1 from Trametinib Potentiates Anti-PD-1 Efficacy in Tumors Established from Chemotherapy-Primed Pancreatic Cancer Cells
Authors: Pham Thao D. , Metropulos Anastasia E. , Mubin Nida , Becker Jeffrey H. , Shah Dhavan , Spaulding Christina , Shields Mario A. , Bentrem David J. , Munshi Hidayatullah G.
Published: December 2024

Supplementary Table S1
Figure S1 from Targeting the Synthetic Lethal Relationship between FOCAD and TUT7 Represents a Potential Therapeutic Opportunity for TUT4/7 Small-Molecule Inhibitors in Cancer
Authors: Triboulet Robinson , Sadykov Khikmet , Harvey Darren M. , Wilson David M. , Steinbaugh Michael J. , Mayo Christopher B. , Hawley Dillon , Madanjian Andrew , Fyfe Corey , Bracken Christina , Rivera-Rivera Izarys , Ericsson Anna , Snyder Andrew R. , Knutson Sarah K. , Stein Ross L. , Gibaja Veronica , Ghosh Shomir , Campbell Robert M.
Published: December 2024

Related to Figure 2
Supplemental Fig. S8 from Trametinib Potentiates Anti-PD-1 Efficacy in Tumors Established from Chemotherapy-Primed Pancreatic Cancer Cells
Authors: Pham Thao D. , Metropulos Anastasia E. , Mubin Nida , Becker Jeffrey H. , Shah Dhavan , Spaulding Christina , Shields Mario A. , Bentrem David J. , Munshi Hidayatullah G.
Published: December 2024

Supplemental Fig. S8. The KPC-FIO tumors and conditioned media from the KPC-FIO cells are enriched in pro-inflammatory and T cell chemoattractive cytokines. A. Established subcutaneously implanted 2138 and 2138-FIO tumors were evaluated for cytokine expression by cytokine array. About 3 to 5 tumors per group were pooled for analysis. B. 2138 and 2138-FIO, cultured in the media supplemented with 2% FBS for 48 hours, were evaluated for cytokine expression by cytokine array. Arrows indicate overlapping cytokines between the tumors and conditioned media. Signal intensity was analyzed by ImageJ. Error bar ± SD from technical replicates. C. Heatmap summarizing normalized signal intensity of cytokines detected in the tumors versus conditioned media (CM). UD, undetected.
Supplemental Fig. S6 from Trametinib Potentiates Anti-PD-1 Efficacy in Tumors Established from Chemotherapy-Primed Pancreatic Cancer Cells
Authors: Pham Thao D. , Metropulos Anastasia E. , Mubin Nida , Becker Jeffrey H. , Shah Dhavan , Spaulding Christina , Shields Mario A. , Bentrem David J. , Munshi Hidayatullah G.
Published: December 2024

Supplemental Fig. S6. KPC-FIO cells display reduced sensitivity to various combinations of 5FU (F), SN38 (I), and oxaliplatin (O). A, B. Parental KPC (2138 and 3886) and KPC-FIO (2138-FIO and 3886-FIO) cells were treated with vehicle control, increasing doses of F (0 µM, 0.5 µM, 1 µM, 2 µM), increasing doses of SN38 (0 nM, 50 nM, 100, 200 nM), increasing doses of O (0 µM, 1 µM, 4 µM, 8 µM) or a combination of these doses. After 72 hours, the effects of drug treatments on cell proliferation were evaluated by WST1 assay. Values were normalized against the vehicle-treated sample and visualized by the depicted heatmap. Heatmaps are representative of three biological replicates.
Supplementary Figure S4 from Integrated Imaging Probe and Bispecific Antibody Development Enables In Vivo Targeting of Glypican-3–Expressing Hepatocellular Carcinoma
Authors: Habibollahi Peiman , Gurevich Alexey , Hui James Z. , Weinfurtner Kelly , McClung George , Adler Justin , Soulen Michael C. , Kaplan David E. , Nadolski Gregory J. , Hunt Stephen J. , Tsourkas Andrew , Gade Terence P.
Published: December 2024

Supplementary Figure 4: In-Vivo treatment schedule of injections and imaging. After i.p. injection of saline or T-cells, tumors were injected with saline, scGPC3/CD3, or the GPC3/CD3 bispecific antibody every 12 hours for a total of five injections. This serial injection sequence was repeated on the fourth day following the first injection. Mice were euthanized on day 14 with tumor tissues preserved for histology.
Supplementary Figure S3 from Integrated Imaging Probe and Bispecific Antibody Development Enables In Vivo Targeting of Glypican-3–Expressing Hepatocellular Carcinoma
Authors: Habibollahi Peiman , Gurevich Alexey , Hui James Z. , Weinfurtner Kelly , McClung George , Adler Justin , Soulen Michael C. , Kaplan David E. , Nadolski Gregory J. , Hunt Stephen J. , Tsourkas Andrew , Gade Terence P.
Published: December 2024

Supplementary Figure S3: GPC3-specific targeting peptide has a similar binding pattern to HCC samples compared to immunostaining with GPC3 antibody. (A-D) Representative contiguous slides from HCC samples stained with GPC3 antibody (A, B) and GPC3-specific peptide (C, D) demonstrate similar staining patterns. HCC, hepatocellular carcinoma.
Supplementary Figure-3 from TEAD2 Promotes Hepatocellular Carcinoma Development and Sorafenib Resistance via TAK1 Transcriptional Activation
Authors: Zhang Yahui , Ren Yidan , Dong Guoying , Jiao Qinlian , Guo Nan , Gao Ping , Li Ya , Wang Yunshan , Zhao Wei
Published: December 2024

Supplementary Figure-3
Supplementary Figure-1 from TEAD2 Promotes Hepatocellular Carcinoma Development and Sorafenib Resistance via TAK1 Transcriptional Activation
Authors: Zhang Yahui , Ren Yidan , Dong Guoying , Jiao Qinlian , Guo Nan , Gao Ping , Li Ya , Wang Yunshan , Zhao Wei
Published: December 2024

Supplementary Figure-1
Table S5 from Ruthenium Drug BOLD-100 Regulates BRAFMT Colorectal Cancer Cell Apoptosis through AhR/ROS/ATR Signaling Axis Modulation
Authors: Griffin Daryl , Carson Robbie , Moss Debbie , Sessler Tamas , Lavin Deborah , Tiwari Vijay K. , Karelia Shivaali , Kennedy Richard , Savage Kienan I. , McDade Simon , Carie Adam , Pankovich Jim , Bazett Mark , Van Schaeybroeck Sandra
Published: December 2024

Table S5: BOLD-100 Compound Screen
Table S2 from Ruthenium Drug BOLD-100 Regulates BRAFMT Colorectal Cancer Cell Apoptosis through AhR/ROS/ATR Signaling Axis Modulation
Authors: Griffin Daryl , Carson Robbie , Moss Debbie , Sessler Tamas , Lavin Deborah , Tiwari Vijay K. , Karelia Shivaali , Kennedy Richard , Savage Kienan I. , McDade Simon , Carie Adam , Pankovich Jim , Bazett Mark , Van Schaeybroeck Sandra
Published: December 2024

Table S2: TSG siRNA screen
Supplementary Figure 1 from Ruthenium Drug BOLD-100 Regulates BRAFMT Colorectal Cancer Cell Apoptosis through AhR/ROS/ATR Signaling Axis Modulation
Authors: Griffin Daryl , Carson Robbie , Moss Debbie , Sessler Tamas , Lavin Deborah , Tiwari Vijay K. , Karelia Shivaali , Kennedy Richard , Savage Kienan I. , McDade Simon , Carie Adam , Pankovich Jim , Bazett Mark , Van Schaeybroeck Sandra
Published: December 2024

Response of BRAFMT CRC cells to BOLD-100.
Supplementary Table 8 from EHMT1/2 Inhibition Promotes Regression of Therapy-Resistant Ovarian Cancer Tumors in a CD8 T-cell–Dependent Manner
Authors: Nguyen Lily L. , Watson Zachary L. , Ortega Raquel , Woodruff Elizabeth R. , Jordan Kimberly R. , Iwanaga Ritsuko , Yamamoto Tomomi M. , Bailey Courtney A. , To Francis , Lin Shujian , Villagomez Fabian R. , Jeong Abigail D. , Guntupalli Saketh R. , Behbakht Kian , Gibaja Veronica , Arnoult Nausica , Chuong Edward B. , Bitler Benjamin G.
Published: December 2024

Hallmark pathways negatively enriched in ID8-R cells treated with combinatory UNC0642/Olaparib compared to UNC0642 alone.
Supplementary Table 11 from EHMT1/2 Inhibition Promotes Regression of Therapy-Resistant Ovarian Cancer Tumors in a CD8 T-cell–Dependent Manner
Authors: Nguyen Lily L. , Watson Zachary L. , Ortega Raquel , Woodruff Elizabeth R. , Jordan Kimberly R. , Iwanaga Ritsuko , Yamamoto Tomomi M. , Bailey Courtney A. , To Francis , Lin Shujian , Villagomez Fabian R. , Jeong Abigail D. , Guntupalli Saketh R. , Behbakht Kian , Gibaja Veronica , Arnoult Nausica , Chuong Edward B. , Bitler Benjamin G.
Published: December 2024

Hallmark pathways enriched in ID8-R cells treated with combinatory EZM8266/Olaparib compared to DMSO control.
Supplementary Figure 4 from EHMT1/2 Inhibition Promotes Regression of Therapy-Resistant Ovarian Cancer Tumors in a CD8 T-cell–Dependent Manner
Authors: Nguyen Lily L. , Watson Zachary L. , Ortega Raquel , Woodruff Elizabeth R. , Jordan Kimberly R. , Iwanaga Ritsuko , Yamamoto Tomomi M. , Bailey Courtney A. , To Francis , Lin Shujian , Villagomez Fabian R. , Jeong Abigail D. , Guntupalli Saketh R. , Behbakht Kian , Gibaja Veronica , Arnoult Nausica , Chuong Edward B. , Bitler Benjamin G.
Published: December 2024

EHMT inhibition is well-tolerated and the anti-tumor response is dose-dependent.
Supplementary Figure 2 from EHMT1/2 Inhibition Promotes Regression of Therapy-Resistant Ovarian Cancer Tumors in a CD8 T-cell–Dependent Manner
Authors: Nguyen Lily L. , Watson Zachary L. , Ortega Raquel , Woodruff Elizabeth R. , Jordan Kimberly R. , Iwanaga Ritsuko , Yamamoto Tomomi M. , Bailey Courtney A. , To Francis , Lin Shujian , Villagomez Fabian R. , Jeong Abigail D. , Guntupalli Saketh R. , Behbakht Kian , Gibaja Veronica , Arnoult Nausica , Chuong Edward B. , Bitler Benjamin G.
Published: December 2024

Geneset Enrichment Analysis and TEtranscript Analysis of ID8-OR cells.
Data from TEAD2 Promotes Hepatocellular Carcinoma Development and Sorafenib Resistance via TAK1 Transcriptional Activation
Authors: Zhang Yahui , Ren Yidan , Dong Guoying , Jiao Qinlian , Guo Nan , Gao Ping , Li Ya , Wang Yunshan , Zhao Wei
Published: December 2024

Abstract
Hepatocellular carcinoma (HCC) is the most prevalent type of liver cancer, yet the effectiveness of treatment for patients with HCC is significantly hindered by the development of drug resistance to sorafenib. Through the application of accessibility sequencing to examine drug-resistant HCC tissues, we identified substantial alterations in chromatin accessibility in sorafenib-resistant patient-derived xenograft models. Employing multiomics data integration analysis, we confirmed that the key transcription factor TEAD2, which plays an important role in the Hippo signaling pathway, is a key factor in regulating sorafenib resistance in HCC. Functional assays illustrated that TEAD2 plays a role in promoting HCC progression and enhancing resistance to sorafenib. Mechanistically, we demonstrated that TEAD2 binds to the TAK1 promoter to modulate its expression. Furthermore, we established the involvement of TAK1 in mediating TEAD2-induced sorafenib resistance in HCC, a finding supported by the effectiveness of TAK1 inhibitors. Our research highlights that targeting the TEAD2-TAK1 axis can effectively mitigate drug resistance in patients with HCC receiving sorafenib treatment, offering a novel approach for enhancing the treatment outcomes and prognosis of individuals with HCC.

Implications: Targeting the TEAD2-TAK1 axis presents a promising therapeutic strategy to overcome sorafenib resistance in HCC, potentially improving treatment outcomes and prognosis for patients.
Data from EHMT1/2 Inhibition Promotes Regression of Therapy-Resistant Ovarian Cancer Tumors in a CD8 T-cell–Dependent Manner
Authors: Nguyen Lily L. , Watson Zachary L. , Ortega Raquel , Woodruff Elizabeth R. , Jordan Kimberly R. , Iwanaga Ritsuko , Yamamoto Tomomi M. , Bailey Courtney A. , To Francis , Lin Shujian , Villagomez Fabian R. , Jeong Abigail D. , Guntupalli Saketh R. , Behbakht Kian , Gibaja Veronica , Arnoult Nausica , Chuong Edward B. , Bitler Benjamin G.
Published: December 2024

Abstract
Poly ADP-ribose polymerase inhibitors (PARPi) are first-line maintenance therapy for ovarian cancer and an alternative therapy for several other cancer types. However, PARPi-resistance is rising, and there is currently an unmet need to combat PARPi-resistant tumors. Here, we created an immunocompetent, PARPi-resistant mouse model to test the efficacy of combinatory PARPi and euchromatic histone methyltransferase 1/2 inhibitor (EHMTi) in the treatment of PARPi-resistant ovarian cancer. We discovered that inhibition of EHMT1/2 resensitizes cells to PARPi. Markedly, we show that single EHMTi and combinatory EHMTi/PARPi significantly reduced PARPi-resistant tumor burden and that this reduction is partially dependent on CD8 T cells. Altogether, our results show a low-toxicity drug that effectively treats PARPi-resistant ovarian cancer in an immune-dependent manner, supporting its entry into clinical development and potential incorporation of immunotherapy.

Implications: Targeting the epigenome of therapy-resistant ovarian cancer induces an antitumor response mediated in part through an antitumor immune response.
Data from Oncogenic HRAS Induces Metformin Resistance in Head and Neck Cancer by Promoting Glycolytic Metabolism
Authors: Wu Xingyu , Adame-Garcia Sendi Rafael , Koshizuka Keiichi , Vo Pham Thuy Tien , Hoang Thomas S. , Sato Kuniaki , Izumi Hiroki , Goto Yusuke , Allevato Michael M. , Wood Kris C. , Lippman Scott M. , Gutkind Jorge Silvio
Published: December 2024

Abstract
Metformin administration has recently emerged as a candidate strategy for the prevention of head and neck squamous cell carcinoma (HNSCC). However, the intricate relationship between genetic alterations in HNSCC and metformin sensitivity is still poorly understood, which prevents the stratification of patients, harboring oral premalignant lesions that may benefit from the chemopreventive activity of metformin. In this study, we investigate the impact of prevalent mutations in HNSCC on response to metformin. Notably, we found that the expression of oncogenic HRAS mutants confers resistance to metformin in isogenic HNSCC cell systems, and that HNSCC cells harboring endogenous HRAS mutations display limited sensitivity to metformin. Remarkably, we found that metformin fails to reduce activation of the mTOR pathway in HRAS oncogene-expressing HNSCC cells in vitro and in vivo, correlating with reduced tumor suppressive activity. Mechanistically, we found that this process depends on the ability of HRAS to enhance glycolytic metabolism, thereby suppressing the requirement for oxidative phosphorylation to maintain the cellular energetic balance. Overall, our study revealed that HNSCC cells with oncogenic HRAS mutations exhibit diminished metformin sensitivity, thus shedding light on a potential mechanism of treatment resistance. This finding may also help explain the limited clinical responses to metformin in cancers with RAS mutations. Ultimately, our study underscores the importance of understanding the impact of the genetic landscape in tailoring precision cancer-preventive approaches in the context of HNSCC and other cancers that are characterized by the presence of a defined premalignant state, and therefore, are amenable to cancer interception strategies.

Prevention Relevance: Our findings highlight the challenges of using metformin for cancer prevention in RAS-mutant cancers, where elevated glycolysis may reduce drug efficacy. This underscores the need to explore metformin’s potential in early, premalignant stages, before metabolic shifts render it less effective.
Supplementary Movie 1 from Targeting BTN2A1 Enhances Vγ9Vδ2 T-Cell Effector Functions and Triggers Tumor Cell Pyroptosis
Authors: Le Floch Anne-Charlotte , Imbert Caroline , Boucherit Nicolas , Gorvel Laurent , Fattori Stéphane , Orlanducci Florence , Le Roy Aude , Archetti Lorenzo , Crescence Lydie , Panicot-Dubois Laurence , Dubois Christophe , Vey Norbert , Briantais Antoine , Anastasio Amandine , Cano Carla , Guittard Geoffrey , Frechin Mathieu , Olive Daniel
Published: December 2024

Visualization of Vγ9Vδ2 T cells (E) and SUP-T1 (T) coculture using a label-free method within 20 hours. Ratio T/E = 1/2. Cells treated with 10ug/ml of mIgG1 control antibody.
Figure S7 from CAR T Cells Engineered to Secrete IFNκ Induce Tumor Ferroptosis via an IFNAR/STAT1/ACSL4 Axis
Authors: Gao Yaoxin , Liu Shasha , Huang Yifan , Wang Hui , Zhao Yuyu , Cui Xuyang , Peng Yajing , Li Feng , Zhang Yi
Published: December 2024

IFN-κ-CD276-CAR-T cells inhibited the tumor growth in a dose-dependent manner.
Raw data from Targeting BTN2A1 Enhances Vγ9Vδ2 T-Cell Effector Functions and Triggers Tumor Cell Pyroptosis
Authors: Le Floch Anne-Charlotte , Imbert Caroline , Boucherit Nicolas , Gorvel Laurent , Fattori Stéphane , Orlanducci Florence , Le Roy Aude , Archetti Lorenzo , Crescence Lydie , Panicot-Dubois Laurence , Dubois Christophe , Vey Norbert , Briantais Antoine , Anastasio Amandine , Cano Carla , Guittard Geoffrey , Frechin Mathieu , Olive Daniel
Published: December 2024

Raw data
Figure S6 from CAR T Cells Engineered to Secrete IFNκ Induce Tumor Ferroptosis via an IFNAR/STAT1/ACSL4 Axis
Authors: Gao Yaoxin , Liu Shasha , Huang Yifan , Wang Hui , Zhao Yuyu , Cui Xuyang , Peng Yajing , Li Feng , Zhang Yi
Published: December 2024

Generation of CARs.
Figure S10 from Targeting BTN2A1 Enhances Vγ9Vδ2 T-Cell Effector Functions and Triggers Tumor Cell Pyroptosis
Authors: Le Floch Anne-Charlotte , Imbert Caroline , Boucherit Nicolas , Gorvel Laurent , Fattori Stéphane , Orlanducci Florence , Le Roy Aude , Archetti Lorenzo , Crescence Lydie , Panicot-Dubois Laurence , Dubois Christophe , Vey Norbert , Briantais Antoine , Anastasio Amandine , Cano Carla , Guittard Geoffrey , Frechin Mathieu , Olive Daniel
Published: December 2024

Supplementary Figure S10. The caspase-3-specific inhibitor zDEVD-FMK inhibits the cleavage of GSDME.
Figure S1 from Targeting BTN2A1 Enhances Vγ9Vδ2 T-Cell Effector Functions and Triggers Tumor Cell Pyroptosis
Authors: Le Floch Anne-Charlotte , Imbert Caroline , Boucherit Nicolas , Gorvel Laurent , Fattori Stéphane , Orlanducci Florence , Le Roy Aude , Archetti Lorenzo , Crescence Lydie , Panicot-Dubois Laurence , Dubois Christophe , Vey Norbert , Briantais Antoine , Anastasio Amandine , Cano Carla , Guittard Geoffrey , Frechin Mathieu , Olive Daniel
Published: December 2024

Supplementary Figure S1. Gating strategy of ALL blasts and determination of the relative number of BTN2A and BTN3A molecules.
Supplementary Tables from Integrated Germline and Somatic Features Reveal Divergent Immune Pathways Driving Response to Immune Checkpoint Blockade
Authors: Sears Timothy J. , Pagadala Meghana S. , Castro Andrea , Lee Ko-han , Kong JungHo , Tanaka Kairi , Lippman Scott M. , Zanetti Maurizio , Carter Hannah
Published: December 2024

Supplementary Tables S1-S8
Supplementary Table 2 from Cannabidiol Enhances Atezolizumab Efficacy by Upregulating PD-L1 Expression via the cGAS–STING Pathway in Triple-Negative Breast Cancer Cells
Authors: Kim Bu Gyeom , Kim Bo Ram , Kim Dae Yeong , Kim Woo Young , Kang Sanghee , Lee Sun Il , Oh Sang Cheul
Published: December 2024

Antibodies for cell surface PD-L1 measurement
Figure S9 from Integrated Germline and Somatic Features Reveal Divergent Immune Pathways Driving Response to Immune Checkpoint Blockade
Authors: Sears Timothy J. , Pagadala Meghana S. , Castro Andrea , Lee Ko-han , Kong JungHo , Tanaka Kairi , Lippman Scott M. , Zanetti Maurizio , Carter Hannah
Published: December 2024

Fig S9. Kaplan-Meier curve of overall survival of responders only in MHC-II reliant patients vs MHC-I reliant patients for discovery group with Van Allen cohort removed.
Figure S7 from Integrated Germline and Somatic Features Reveal Divergent Immune Pathways Driving Response to Immune Checkpoint Blockade
Authors: Sears Timothy J. , Pagadala Meghana S. , Castro Andrea , Lee Ko-han , Kong JungHo , Tanaka Kairi , Lippman Scott M. , Zanetti Maurizio , Carter Hannah
Published: December 2024

Fig S7. A. Waterfall plot of ratio of well-presented MHC-II to MHC-I neoantigens across discovery patients. B. Response rates by reliance groupings across discovery patients. Chi squared tests were performed between groups. C. MHC-I presentation pathway damage as a proportion of total number of mutations split by MHC Reliance grouping. T-tests were used to compare groups. D. Proportion of patients with any damage to MHC-I antigen presentation pathway split by MHC Reliance grouping. Chi squared tests were performed between groups. E. Immunoediting in MHC-II Reliant patients measured by SOPRANO immune dN/dS. T test was used to compare means between patients with and without MHC-I pathway damage. F. TFH cell infiltration estimates stratified by MHC-reliance grouping and ICB response. Mann-Whitney U tests were used to compare means between groups.
Figure S3 from Inflammation Mediated by Gut Microbiome Alterations Promotes Lung Cancer Development and an Immunosuppressed Tumor Microenvironment
Authors: Rahal Zahraa , Liu Yuejiang , Peng Fuduan , Yang Sujuan , Jamal Mohamed A. , Sharma Manvi , Moreno Hannah , Damania Ashish V. , Wong Matthew C. , Ross Matthew C. , Sinjab Ansam , Zhou Tieling , Chen Minyue , Tarifa Reischle Inti , Feng Jiping , Chukwuocha Chidera , Tang Elizabeth , Abaya Camille , Lim Jamie K. , Leung Cheuk Hong , Lin Heather Y. , Deboever Nathaniel , Lee Jack J. , Sepesi Boris , Gibbons Don L. , Wargo Jennifer A. , Fujimoto Junya , Wang Linghua , Petrosino Joseph F. , Ajami Nadim J. , Jenq Robert R. , Moghaddam Seyed Javad , Cascone Tina , Hoffman Kristi , Kadara Humam
Published: December 2024

Supplementary figure S3. Immune changes within the local gut environment and the systemic circulation induced by gut microbiome changes.
Figure S2 from Inflammation Mediated by Gut Microbiome Alterations Promotes Lung Cancer Development and an Immunosuppressed Tumor Microenvironment
Authors: Rahal Zahraa , Liu Yuejiang , Peng Fuduan , Yang Sujuan , Jamal Mohamed A. , Sharma Manvi , Moreno Hannah , Damania Ashish V. , Wong Matthew C. , Ross Matthew C. , Sinjab Ansam , Zhou Tieling , Chen Minyue , Tarifa Reischle Inti , Feng Jiping , Chukwuocha Chidera , Tang Elizabeth , Abaya Camille , Lim Jamie K. , Leung Cheuk Hong , Lin Heather Y. , Deboever Nathaniel , Lee Jack J. , Sepesi Boris , Gibbons Don L. , Wargo Jennifer A. , Fujimoto Junya , Wang Linghua , Petrosino Joseph F. , Ajami Nadim J. , Jenq Robert R. , Moghaddam Seyed Javad , Cascone Tina , Hoffman Kristi , Kadara Humam
Published: December 2024

Supplementary figure S2. scRNA-seq of the colonic lamina propria in the syngeneic mice following FMT.
Figure S6 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors
Authors: Zhang Zhen , Zhao Xuan , Zhao Qitai , Chen Xinfeng , Li Congcong , Liu Yaqing , Shen Chunyi , Song Lijie , Miao Lijun , Guo Fuyou , Mou Xiaoning , Zhao Jie , Gu Weiyue , Zhang Yi
Published: December 2024

Supplementary Figure S6. Flow cytometry gating strategy for T cell function assay and transduction efficacy assay.
Figure S3 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors
Authors: Zhang Zhen , Zhao Xuan , Zhao Qitai , Chen Xinfeng , Li Congcong , Liu Yaqing , Shen Chunyi , Song Lijie , Miao Lijun , Guo Fuyou , Mou Xiaoning , Zhao Jie , Gu Weiyue , Zhang Yi
Published: December 2024

Supplementary Figure S3. Clustering of scRNA-seq data.
Figure S5 from PTPRZ1-Targeting RNA CAR T Cells Exert Antigen-Specific and Bystander Antitumor Activity in Glioblastoma
Authors: Martinez Bedoya Darel , Marinari Eliana , Davanture Suzel , Castillo Cantero Luis , Erraiss Sarah , Dockerill Millicent , Barluenga Sofia , Winssinger Nicolas , Schaller Karl , Bijlenga Philippe , Momjian Shahan , Voize Christel , Tissot Stéphanie R. , Kandalaft Lana E. , Hammel Philippe , Cosson Pierre , Walker Paul R. , Dutoit Valérie , Migliorini Denis
Published: December 2024

Use of Jurkat triple reporter cells to assess CAR tonic signaling and specificity
Supplementary Table S13 from Spatially Resolved Whole-Transcriptomic and Proteomic Profiling of Lung Cancer and Its Immune Microenvironment According to PD-L1 Expression
Authors: Koh Jaemoon , Lee Dongjoo , Kim Sehui , Song Seung Geun , Han Bogyeong , Jeong Hyein , Kim Young A , Keam Bhumsuk , Lee Se-Hoon , Kim Kwangsoo , Jeon Yoon Kyung , Chung Doo Hyun
Published: December 2024

The most up- or downregulated gene sets in tumor cells between IF_PDL1L and ID_PDL1H
Supplementary Table S11 from Spatially Resolved Whole-Transcriptomic and Proteomic Profiling of Lung Cancer and Its Immune Microenvironment According to PD-L1 Expression
Authors: Koh Jaemoon , Lee Dongjoo , Kim Sehui , Song Seung Geun , Han Bogyeong , Jeong Hyein , Kim Young A , Keam Bhumsuk , Lee Se-Hoon , Kim Kwangsoo , Jeon Yoon Kyung , Chung Doo Hyun
Published: December 2024

The most up- or downregulated gene sets in tumor cells between IF_PDL1H and IF_PDL1L
Supplementary Figure S5 from Spatially Resolved Whole-Transcriptomic and Proteomic Profiling of Lung Cancer and Its Immune Microenvironment According to PD-L1 Expression
Authors: Koh Jaemoon , Lee Dongjoo , Kim Sehui , Song Seung Geun , Han Bogyeong , Jeong Hyein , Kim Young A , Keam Bhumsuk , Lee Se-Hoon , Kim Kwangsoo , Jeon Yoon Kyung , Chung Doo Hyun
Published: December 2024

The characteristics of tumor cells based on the degree of immune cell infiltration and tumor PD-L1 expression in the tumor microenvironment.
Supplementary Figure S3 from Spatially Resolved Whole-Transcriptomic and Proteomic Profiling of Lung Cancer and Its Immune Microenvironment According to PD-L1 Expression
Authors: Koh Jaemoon , Lee Dongjoo , Kim Sehui , Song Seung Geun , Han Bogyeong , Jeong Hyein , Kim Young A , Keam Bhumsuk , Lee Se-Hoon , Kim Kwangsoo , Jeon Yoon Kyung , Chung Doo Hyun
Published: December 2024

The characteristics of immune cells according to tumor PD-L1 expression in immune deficient tumor microenvironment.
Table S1 from Hyper-Interferon Sensitive Influenza Induces Adaptive Immune Responses and Overcomes Resistance to Anti–PD-1 in Murine Non–Small Cell Lung Cancer
Authors: Du Yushen , Salehi-Rad Ramin , Zhang Tian-hao , Crosson William P. , Abascal Jensen , Chen Dongdong , Shi Yuan , Jiang Hong , Tseng Yen-Wen , Ma Xi , Hong Mengying , Wang Sihan , Wang Xijuan , Tang Kejun , Hu Shiyao , Li Yuting , Ni Shaokai , Cai Yiqi , Tappuni Shahed , Shen Yong , Liu Bin , Sun Ren
Published: December 2024

Primer sequences for real-time PCR
Figure S2 from Hyper-Interferon Sensitive Influenza Induces Adaptive Immune Responses and Overcomes Resistance to Anti–PD-1 in Murine Non–Small Cell Lung Cancer
Authors: Du Yushen , Salehi-Rad Ramin , Zhang Tian-hao , Crosson William P. , Abascal Jensen , Chen Dongdong , Shi Yuan , Jiang Hong , Tseng Yen-Wen , Ma Xi , Hong Mengying , Wang Sihan , Wang Xijuan , Tang Kejun , Hu Shiyao , Li Yuting , Ni Shaokai , Cai Yiqi , Tappuni Shahed , Shen Yong , Liu Bin , Sun Ren
Published: December 2024

HIS inhibits NSCLC tumors growth in mice
Validated questionnaires for the assessment of Italian patients with pelvic floor dysfunctions: a systematic review.
Authors: Braga Andrea , Vigna Annalisa , Barba Marta , Caccia Giorgio , Papadia Andrea , Campitiello Maria Rosaria , Serati Maurizio , Frigerio Matteo
Published: December 2024

Background:
Pelvic floor dysfunctions (PFDs) have a complex, multifactorial pathophysiology that impacts women's health and must be identified to provide the most appropriate care and treatment. Therefore, symptom and quality of life (QoL) questionnaires, briefly identified as patient-reported outcomes (PROs), have been developed. Despite the large number of questionnaires available for the assessment of PFDs and QoL-related issues in English, few of them have been validated for the Italian language.
Objectives:
The aim of this article is to systematically review the literature on Italian-language validated PROs for PFDs assessment, along with practical information on literature references and suggestions on how to obtain each individual questionnaire.
Methods:
A systematic review according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Statement was performed up to 1 March 2024. PubMed/MEDLINE databases and websites were used to identify validated questionnaires in Italian language for PFDs. Once identified, the possibility of obtaining a copy of the questionnaire was checked, and the steps to obtain one are given in the text.
Outcome:
Thirty-five Italian-validated questionnaires were included: 17 out of 35 (48.6%) questionnaires focused on Lower urinary tract symptoms, 1 (2.8%) on genital prolapse symptoms, 8 (22.8%) on sexuality, 3 (8.6%) on bowel symptoms and 6 (17.2%) on pelvic dysfunctions. The literature search turned up seven more Italian PRO validation papers than the previous review. Specifically, the newly validated PROs include: Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12), Sexual Desire and Erotic Fantasies (SDEF) Questionnaire, Sexual Inhibition/Sexual Excitation Scales (SIS/SES), 12-Item Sexual Distress Scale (SDS) and 5-Item Sexual Distress Scale-Short Form (SDS-SF), Vaizey and Wexner and fecal incontinence severity index (FISI) questionnaires, Pelvic Floor Distress Inventory (PFDI-20) questionnaire, Intermittent Catheterization Acceptance Test (I-CAT).
Conclusions and outlook:
This systematic review is intended to be a tool to promote the adoption of appropriate PROs when studying PFDs in Italian patients.